Broker’s Call: Ipca Laboratories (Buy)

Why It Matters

The earnings beat and margin expansion signal stronger profitability for Ipca, positioning it for upside in a competitive Indian pharma market and justifying a higher valuation target.

Key Takeaways

• EBITDA rose 19% YoY, beating estimates.
• Domestic formulation revenue grew 12% year‑on‑year.
• Export API surged 26% in 9MFY26.
• Gross margin expanded 400 bps excluding Unichem.
• Target price set at ₹1,710, 17× EV/EBITDA FY28E.

Pulse Analysis

India’s pharmaceutical sector continues to benefit from a blend of domestic demand and export opportunities, and Ipca Laboratories is emerging as a notable beneficiary. The company’s latest nine‑month results show a solid top‑line trajectory, with revenue climbing to ₹2,400 crore driven primarily by a 12% rise in domestic formulations and a 17% jump in export formulations. While API sales remained flat overall, the export API segment posted a striking 26% growth, indicating a re‑acceleration in a historically volatile business line. This balanced performance underscores Ipca’s diversified product mix, which helps mitigate cyclical pressures in any single segment.

Margin dynamics are a key differentiator for Ipca. The firm reported a 400‑basis‑point gross‑margin expansion excluding its Unichem subsidiary, pushing consolidated margins to 72.5%. This improvement stems from a favorable product‑mix shift toward higher‑margin formulations and softer raw‑material costs, factors that are likely to persist as the company leverages its scale. Additionally, the modest forex loss of ₹3.5 crore was offset by stronger operating efficiencies, resulting in an adjusted EBITDA that outperformed the broker’s forecast by ₹50 crore. Such financial resilience positions Ipca to sustain profitability even amid currency volatility.

From an investment perspective, the broker’s revised target price of ₹1,710 reflects a 17× EV/EBITDA multiple for FY28E, a premium that assumes continued margin expansion and export growth. The 31% rise in net profit and a 35% EBITDA boost after adjusting for Unichem suggest that the company’s core operations are gaining momentum. Analysts will watch the API recovery closely, as a sustained export rebound could further enhance earnings visibility. Overall, Ipca’s blend of strong earnings, expanding margins, and strategic export positioning makes it a compelling buy for investors seeking exposure to India’s growing pharma landscape.